Christopher Simon - 16 May 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President & CEO, Director
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Issuer symbol
HAE
Transactions as of
16 May 2025
Net transactions value
$0
Form type
4
Filing time
20 May 2025, 17:10:55 UTC
Previous filing
19 May 2025
Next filing
27 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Simon, Christopher President & CEO, Director 125 SUMMER STREET, BOSTON /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon 20 May 2025 0001674993

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +21,405 +6.8% 335,112 16 May 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +46,342 $0.000000 46,342 16 May 2025 Common Stock 46,342 $70.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 This number includes unvested RSUs previously reported.
F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.